Skip to main content

Articles

Page 1 of 13

  1. Hematological malignancies (HMs) encompass a diverse group of blood neoplasms with significant morbidity and mortality. Immunotherapy has emerged as a validated and crucial treatment modality for patients with...

    Authors: Jian Xu, Wenqi Liu, Fengjuan Fan, Bo Zhang, Chunyan Sun and Yu Hu
    Citation: Experimental Hematology & Oncology 2024 13:57
  2. Rearrangements of the mixed lineage leukemia (MLLr) gene are frequently associated with aggressive acute myeloid leukemia (AML). However, the treatment options are limited due to the genomic complexity and dyn...

    Authors: Pinpin Sui, Zhihong Wang, Peng Zhang and Feng Pan
    Citation: Experimental Hematology & Oncology 2024 13:56
  3. Radiotherapy is one of the mainstream approaches for cancer treatment, although the clinical outcomes are limited due to the radioresistance of tumor cells. Hypoxia and metabolic reprogramming are the hallmark...

    Authors: Zheng Shi, Cuilan Hu, Xiaogang Zheng, Chao Sun and Qiang Li
    Citation: Experimental Hematology & Oncology 2024 13:55
  4. Authors: Shiyong Xin, Xiang Liu, Ziyao Li, Xianchao Sun, Rong Wang, Zhenhua Zhang, Xinwei Feng, Liang Jin, Weiyi Li, Chaozhi Tang, Wangli Mei, Qiong Cao, Haojie Wang, Jianguo Zhang, Lijin Feng and Lin Ye
    Citation: Experimental Hematology & Oncology 2024 13:54

    The original article was published in Experimental Hematology & Oncology 2023 12:49

  5. Increasing evidence supports a role for small extracellular vesicles (sEV, including exosomes) in Diffuse Large B-cell lymphoma (DLBCL) progression and resistance to treatment. CD20 and PD-L1 are found on DLBC...

    Authors: Hussein Akil, Hafidha Bentayeb, Marine Aitamer, Chantal Vignoles, Julie Abraham, Nathalie Gachard, Agnès Olivrie, Anne Guyot, Jessica Gobbo, Jean Feuillard, Hamasseh Shirvani and Danielle Troutaud
    Citation: Experimental Hematology & Oncology 2024 13:53
  6. Non-small cell lung cancer (NSCLC) is one of the predominant malignancies globally. Percutaneous thermal ablation (PTA) has gained widespread use among NSCLC patients, with the potential to elicit immune respo...

    Authors: Hanbo Pan, Yu Tian, Siyu Pei, Wanlin Yang, Yanyang Zhang, Zenan Gu, Hongda Zhu, Ningyuan Zou, Jiaqi Zhang, Long Jiang, Yingjie Hu, Shengping Shen, Kai Wang, Haizhen Jin, Ziming Li, Yanyun Zhang…
    Citation: Experimental Hematology & Oncology 2024 13:52
  7. CAR NK cells as vehicles for engineered “off-the-shelf” cellular cancer immunotherapy have attracted significant interest. Nonetheless, a comprehensive comparative assessment of the anticancer activity of CAR ...

    Authors: Lukas Egli, Meike Kaulfuss, Juliane Mietz, Arianna Picozzi, Els Verhoeyen, Christian Münz and Obinna Chijioke
    Citation: Experimental Hematology & Oncology 2024 13:51
  8. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for myeloid malignancies such as some acute myeloid leukemias (AML) and high-risk myelodysplastic syndromes (MDS). ...

    Authors: Anne-Béatrice Notarantonio, Allan Bertrand, Romain Piucco, Ghislain Fievet, Hervé Sartelet, Laura Boulangé, Natalia de Isla, Marcelo De Carvalho Bittencourt, Sébastien Hergalant, Marie-Thérèse Rubio and Maud D’Aveni
    Citation: Experimental Hematology & Oncology 2024 13:50
  9. Leukemias driven by activated, chimeric FGFR1 kinases typically progress to AML which have poor prognosis. Mouse models of this syndrome allow detailed analysis of cellular and molecular changes occurring duri...

    Authors: Tianxiang Hu, Bo Cheng, Atsuko Matsunaga, Ting Zhang, Xiaocui Lu, Hui Fang, Stephanie F. Mori, Xuexiu Fang, Gavin Wang, Hongyan Xu, Huidong Shi and John K. Cowell
    Citation: Experimental Hematology & Oncology 2024 13:49
  10. Cancer is the leading cause of death among older adults. Although the integration of immunotherapy has revolutionized the therapeutic landscape of cancer, the complex interactions between age and immunotherapy...

    Authors: Junlei Hou, Shuanglong Xie, Jianbao Gao, Tao Jiang, Enjian Zhu, Xuezhi Yang, Zheng Jin, Haixia Long, Anmei Zhang, Fei Yang, Lujing Wang, Haoran Zha, Qingzhu Jia, Bo Zhu and Xinxin Wang
    Citation: Experimental Hematology & Oncology 2024 13:48
  11. Enhanced cellular therapy has emerged as a novel concept following the basis of cellular therapy. This treatment modality applied drugs or biotechnology to directly enhance or genetically modify cells to enhan...

    Authors: Meng-Yao Xu, Na Zeng, Chen-Qian Liu, Jian-Xuan Sun, Ye An, Si-Han Zhang, Jin-Zhou Xu, Xing-Yu Zhong, Si-Yang Ma, Hao-Dong He, Jia Hu, Qi-Dong Xia and Shao-Gang Wang
    Citation: Experimental Hematology & Oncology 2024 13:47
  12. The interaction between programmed cell death ligand 1 (PD-L1), which is expressed on the surface of tumor cells, and programmed cell death 1 (PD-1), which is expressed on T cells, impedes the effective activa...

    Authors: Rong Wang, Shiwei He, Jun Long, Yian Wang, Xianjie Jiang, Mingfen Chen and Jie Wang
    Citation: Experimental Hematology & Oncology 2024 13:46
  13. Histone deacetylase inhibitors (HDACis) are a significant category of pharmaceuticals that have developed in the past two decades to treat multiple myeloma. Four drugs in this category have received approval f...

    Authors: Jingjing Pu, Ting Liu, Xuzhen Wang, Amit Sharma, Ingo G. H. Schmidt-Wolf, Liping Jiang and Jian Hou
    Citation: Experimental Hematology & Oncology 2024 13:45
  14. Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of hematological malignancies with poor survival, while treatment options for relapsed or refractory (R/R) disease remain quite limited, with a median...

    Authors: Huageng Huang, Wei Zhang, Xinyi Deng, He Huang, Zhao Wang, Huangming Hong and Tongyu Lin
    Citation: Experimental Hematology & Oncology 2024 13:44
  15. Chimeric antigen receptors (CAR) are engineered fusion proteins that target T-cells to specific surface antigens of tumor cells to generate effective anti-tumor responses. CAR T-cell therapy is playing an incr...

    Authors: Wenjie Zhang, Sumei Li, Jinlan Long, Shufeng Xie, Minghui Wang, Han Liu and Zhenshu Xu
    Citation: Experimental Hematology & Oncology 2024 13:43
  16. Chemotherapy is a commonly effective treatment for most types of cancer. However, many patients experience a relapse due to minimal residual disease (MRD) after chemotherapy. Previous studies have analyzed the...

    Authors: Yuanhui Liu, Bi Peng, Ziqi Chen, Yimin Shen, Jingmin Zhang and Xianglin Yuan
    Citation: Experimental Hematology & Oncology 2024 13:42
  17. Despite major therapeutic advances for two decades, including the most recently approved anti-HER2 drugs, brain metastatic localizations remain the major cause of death for women with metastatic HER2 breast ca...

    Authors: Eurydice Angeli, Justine Paris, Olivier Le Tilly, Céline Desvignes, Guillaume Gapihan, Didier Boquet, Frédéric Pamoukdjian, Diaddin Hamdan, Marthe Rigal, Florence Poirier, Didier Lutomski, Feriel Azibani, Alexandre Mebazaa, Amaury Herbet, Aloïse Mabondzo, Géraldine Falgarone…
    Citation: Experimental Hematology & Oncology 2024 13:41
  18. Glioblastoma (GBM) is a fatal brain tumour that is traditionally diagnosed based on histological features. Recent molecular profiling studies have reshaped the World Health Organization approach in the classif...

    Authors: Yating Shen, Dexter Kai Hao Thng, Andrea Li Ann Wong and Tan Boon Toh
    Citation: Experimental Hematology & Oncology 2024 13:40
  19. Paradoxically, tumor development and progression can be inhibited and promoted by the immune system. After three stages of immune editing, namely, elimination, homeostasis and escape, tumor cells are no longer...

    Authors: Junli Lu, Yiming Luo, Dean Rao, Tiantian Wang, Zhen Lei, Xiaoping Chen, Bixiang Zhang, Yiwei Li, Bifeng Liu, Limin Xia and Wenjie Huang
    Citation: Experimental Hematology & Oncology 2024 13:39
  20. Rhabdomyosarcoma (RMS), such as other childhood tumors, has witnessed treatment advancements in recent years. However, high-risk patients continue to face poor survival rates, often attributed to the presence ...

    Authors: Gabriel Gallo-Oller, Guillem Pons, Júlia Sansa-Girona, Natalia Navarro, Patricia Zarzosa, Lia García-Gilabert, Paula Cabré-Fernandez, Gabriela Guillén Burrieza, Lorena Valero-Arrese, Miguel F. Segura, José M. Lizcano, José Sánchez de Toledo, Lucas Moreno, Soledad Gallego and Josep Roma
    Citation: Experimental Hematology & Oncology 2024 13:38
  21. Adoptive immunotherapy in the T cell landscape exhibits efficacy in cancer treatment. Over the past few decades, genetically modified T cells, particularly chimeric antigen receptor T cells, have enabled remar...

    Authors: Weihuan Shao, Yiran Yao, Ludi Yang, Xiaoran Li, Tongxin Ge, Yue Zheng, Qiuyi Zhu, Shengfang Ge, Xiang Gu, Renbing Jia, Xin Song and Ai Zhuang
    Citation: Experimental Hematology & Oncology 2024 13:37
  22. Natural killer (NK) cells are effective in attacking tumor cells that escape T cell attack. Memory NK cells are believed to function as potent effector cells in cancer immunotherapy. However, knowledge of thei...

    Authors: Alaa M. Khalifa, Takashi Nakamura, Yusuke Sato and Hideyoshi Harashima
    Citation: Experimental Hematology & Oncology 2024 13:36
  23. VISTA is a well-known immune checkpoint in T cell biology, but its role in innate immunity is less established. Here, we investigated the role of VISTA on anticancer macrophage immunity, with a focus on phagoc...

    Authors: Yusheng Lin, Ghizlane Choukrani, Lena Dubbel, Lena Rockstein, Jimena Alvarez Freile, Yuzhu Qi, Valerie Wiersma, Hao Zhang, Karl-Wilhelm Koch, Emanuele Ammatuna, Jan Jacob Schuringa, Tom van Meerten, Gerwin Huls and Edwin Bremer
    Citation: Experimental Hematology & Oncology 2024 13:35
  24. Mantle cell lymphoma (MCL) is a chronically relapsing malignancy with deregulated cell cycle progression. We analyzed efficacy, mode of action, and predictive markers of susceptibility to palbociclib, an appro...

    Authors: Diana Malarikova, Radek Jorda, Kristyna Kupcova, Jana Senavova, Alexandra Dolnikova, Eva Pokorna, Dmitry Kazantsev, Kristina Nozickova, Dana Sovilj, Celine Bellanger, David Chiron, Ladislav Andera, Vladimir Krystof, Miroslav Strnad, Karel Helman, Magdalena Klanova…
    Citation: Experimental Hematology & Oncology 2024 13:34
  25. Oral microbial dysbiosis contributes to the development of oral squamous cell carcinoma (OSCC). Our previous study showed that Prevotella intermedia (P. intermedia) were enriched in the oral mucosal surface, plaq...

    Authors: Yifan Zhou, Yao Qin, Jingjing Ma, Zhiyuan Li, Weiwei Heng, Lei Zhang, Hong Liu, Ruowei Li, Miaomiao Zhang, Qiao Peng, Pei Ye, Ning Duan, Ting Liu, Wenmei Wang and Xiang Wang
    Citation: Experimental Hematology & Oncology 2024 13:33
  26. The evolutionarily conserved protein FBXO9 acts as a substrate receptor for the SKP1-cullin-1-RBX1 ubiquitin ligase and is implicated in cancer, exhibiting either tumor-suppressive or oncogenic effects dependi...

    Authors: Liang Liu, Xiaodong Chen, Leilei Wu, Kaizong Huang, Zhenyi Wang, Yaolin Zheng, Cheng Zheng, Zhenshan Zhang, Jiayan Chen, Jiaming Wei, Song Chen, Weilin Jin, Jinfei Chen, Dongping Wei and Yaping Xu
    Citation: Experimental Hematology & Oncology 2024 13:32
  27. Sarcoma is a malignant tumor that originates from mesenchymal tissue. The common treatment for sarcoma is surgery supplemented with radiotherapy and chemotherapy. However, patients have a 5-year survival rate ...

    Authors: Jing Zeng, Xianghong Zhang, Zhengjun Lin, Yu Zhang, Jing Yang, Pengcheng Dou and Tang Liu
    Citation: Experimental Hematology & Oncology 2024 13:31
  28. A-to-I RNA editing is an abundant post-transcriptional modification event in hepatocellular carcinoma (HCC). Evidence suggests that adenosine deaminases acting on RNA 1 (ADAR1) correlates to oxidative stress t...

    Authors: Houhong Wang, Xiaoyu Wei, Lu Liu, Junfeng Zhang and Heng Li
    Citation: Experimental Hematology & Oncology 2024 13:30
  29. Mesenchymal stem cells (MSCs) possess multipotent properties that make them promising candidates for immunomodulation and regenerative medicine. However, MSC heterogeneity poses challenges to their research re...

    Authors: Miao Yu, Ke Sui, Zheng Wang and Xi Zhang
    Citation: Experimental Hematology & Oncology 2024 13:29
  30. Although the efficacy of chimeric antigen receptor (CAR)-T cell therapy has been widely demonstrated, its clinical application is hampered by the complexity and fatality of its side effe...

    Authors: Linqin Wang, Yuqi Lv, Linghui Zhou, Shenghao Wu, Yuanyuan Zhu, Shan Fu, Shuyi Ding, Ruimin Hong, Mingming Zhang, Hanjing Yu, Alex H. Chang, Guoqing Wei, Yongxian Hu and He Huang
    Citation: Experimental Hematology & Oncology 2024 13:28
  31. Acute myeloid leukemia (AML) is a highly aggressive hematologic cancer with poor survival across a broad range of molecular subtypes. Development of efficacious and well-tolerable therapies encompassing the ra...

    Authors: Alexander R. Marr, Madeline Halpin, Dominique L. Corbin, Yerdanos Asemelash, Steven Sher, Britten K. Gordon, Ethan C. Whipp, Shaneice Mitchell, Bonnie K. Harrington, Shelley Orwick, Samon Benrashid, Virginia M. Goettl, Vedat Yildiz, Andrew D. Mitchell, Olivia Cahn, Alice S. Mims…
    Citation: Experimental Hematology & Oncology 2024 13:27
  32. A drug conjugate consists of a cytotoxic drug bound via a linker to a targeted ligand, allowing the targeted delivery of the drug to one or more tumor sites. This approach simultaneously reduces drug toxicity ...

    Authors: Ling Zhou, Yunlong Lu, Wei Liu, Shanglong Wang, Lingling Wang, Pengdou Zheng, Guisha Zi, Huiguo Liu, Wukun Liu and Shuang Wei
    Citation: Experimental Hematology & Oncology 2024 13:26
  33. Over the past few years, dual-targeted chimeric antigen receptor (CAR) T-cell therapy has been employed in the management of hematological malignancies to mitigate treatment failure, particularly in cases of a...

    Authors: Jingyi Yang, Hao Guo, Lu Han, Yongping Song and Keshu Zhou
    Citation: Experimental Hematology & Oncology 2024 13:25
  34. Transcription factor GATA1 controls the delicate balance between proliferation, differentiation and apoptosis in both the erythroid and megakaryocytic lineages. In addition to full-length GATA1, there is an GA...

    Authors: Daishi Ishihara, Atsushi Hasegawa, Ikuo Hirano, James Douglas Engel, Masayuki Yamamoto and Ritsuko Shimizu
    Citation: Experimental Hematology & Oncology 2024 13:24
  35. GATA1 plays a critical role in differentiation, proliferation, and apoptosis during erythropoiesis. We developed a Gata1 knock-down allele (Gata1.05) that results in GATA1 expression at 5% of endogenous level. In...

    Authors: Ikuo Hirano, Kanako Abe, James Douglas Engel, Masayuki Yamamoto and Ritsuko Shimizu
    Citation: Experimental Hematology & Oncology 2024 13:23
  36. Hepatocellular carcinoma (HCC) is closely associatedwith chronic liver diseases, particularly liver cirrhosis, which has an altered extracellular matrix (ECM) composition. The influence and its mechanism of th...

    Authors: Xiao-Tian Shen, Sun-Zhe Xie, Xin Zheng, Tian-Tian Zou, Bei-Yuan Hu, Jing Xu, Lu Liu, Yun-Feng Xu, Xu-Feng Wang, Hao Wang, Shun Wang, Le Zhu, Kang-Kang Yu, Wen-Wei Zhu, Lu Lu, Ju-Bo Zhang…
    Citation: Experimental Hematology & Oncology 2024 13:20
  37. Ferroptosis is a new form of nonapoptotic and iron-dependent type of cell death. Glutathione peroxidase-4 (GPX4) plays an essential role in anti-ferroptosis by reducing lipid peroxidation. Although acute myelo...

    Authors: Shuya Feng, Yigang Yuan, Zihan Lin, Min Li, Daijiao Ye, Liuzhi Shi, Danyang Li, Min Zhao, Chen Meng, Xiaofei He, Shanshan Wu, Fang Xiong, Siyu Ye, Junjun Yang, Haifeng Zhuang, Lili Hong…
    Citation: Experimental Hematology & Oncology 2024 13:19
  38. Mixed-lineage leukemia (MLL) fusion gene caused by chromosomal rearrangement is a dominant oncogenic driver in leukemia. Due to having diverse MLL rearrangements and complex characteristics, MLL leukemia treated ...

    Authors: Tian-Qi Chen, Heng-Jing Huang, Shun-Xin Zhu, Xiao-Tong Chen, Ke-Jia Pu, Dan Wang, Yan An, Jun-Yi Lian, Yu-Meng Sun, Yue-Qin Chen and Wen-Tao Wang
    Citation: Experimental Hematology & Oncology 2024 13:18
  39. Patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) often exhibit limited responses to traditional chemotherapy, resulting in poor prognosis. The combination of venet...

    Authors: Xubo Gong, Xin He, Lin Wang, Teng Yu, Weiwei Liu, Huiying Xu, Lan Jin, Xiang Li, Bin Zhang, Zhihua Tao and Wenbin Qian
    Citation: Experimental Hematology & Oncology 2024 13:17
  40. The 2022 European LeukemiaNet (ELN) updated the previous risk classification published in 2017 but the prognostic significance for allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains unclear...

    Authors: Haixiao Zhang, Xinhui Zheng, Wenwen Guo, Yonghui Xia, Rongli Zhang, Weihua Zhai, Xin Chen, Qiaoling Ma, Donglin Yang, Jialin Wei, Aiming Pang, Yi He, Sizhou Feng, Jianxiang Wang, Mingzhe Han and Erlie Jiang
    Citation: Experimental Hematology & Oncology 2024 13:16
  41. Lung adenocarcinoma (LUAD) is the leading cause of cancer-related death globally. Although the gut microbiota's role in the antitumor efficacy of many cancers has been revealed, its involvement in the response...

    Authors: Ting Jiang, Meng Zhang, Shaoyu Hao, Shi Huang, Xin Zheng and Zheng Sun
    Citation: Experimental Hematology & Oncology 2024 13:15
  42. Brexucabtagene autoleucel CAR-T therapy is highly efficacious in overcoming resistance to Bruton’s tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma. However, many patients relapse post CAR-T therapy w...

    Authors: Fangfang Yan, Vivian Jiang, Alexa Jordan, Yuxuan Che, Yang Liu, Qingsong Cai, Yu Xue, Yijing Li, Joseph McIntosh, Zhihong Chen, Jovanny Vargas, Lei Nie, Yixin Yao, Heng-Huan Lee, Wei Wang, JohnNelson R. Bigcal…
    Citation: Experimental Hematology & Oncology 2024 13:14
  43. Glioblastoma multiforme (GBM) stands as a formidable challenge in oncology because of its aggressive nature and severely limited treatment options. Despite decades of research, the survival rates for GBM remai...

    Authors: Charles H. Williams, Leif R. Neitzel, Jessica Cornell, Samantha Rea, Ian Mills, Maya S. Silver, Jovanni D. Ahmad, Konstantin G. Birukov, Anna Birukova, Henry Brem, Betty Tyler, Eli E. Bar and Charles C. Hong
    Citation: Experimental Hematology & Oncology 2024 13:13
  44. Leukemias are refractory hematological malignancies, characterized by marked intrinsic heterogeneity which poses significant obstacles to effective treatment. However, traditional bulk sequencing techniques ha...

    Authors: Jianche Liu, Penglei Jiang, Zezhen Lu, Zebin Yu and Pengxu Qian
    Citation: Experimental Hematology & Oncology 2024 13:12
  45. KRAS mutation is one of the most common oncogenic drivers in NSCLC, however, the response to immunotherapy is heterogeneous owing to the distinct co-occurring genomic alterations. KRAS/LKB1 co-mutated lung adenoc...

    Authors: Meng Qiao, Fei Zhou, Xinyu Liu, Tao Jiang, Haowei Wang, Xuefei Li, Chao Zhao, Lei Cheng, Xiaoxia Chen, Shengxiang Ren, Zaiqi Wang and Caicun Zhou
    Citation: Experimental Hematology & Oncology 2024 13:11
  46. Metabolic reprogramming is an emerging hallmark of cancer cells, enabling them to meet increased nutrient and energy demands while withstanding the challenging microenvironment. Cancer cells can switch their m...

    Authors: Jianqiang Yang, Chloe Shay, Nabil F. Saba and Yong Teng
    Citation: Experimental Hematology & Oncology 2024 13:10
  47. t(8;21)(q22;q22) is one of the most frequent chromosomal abnormalities in acute myeloid leukemia (AML), leading to the generation of the fusion protein AML1-ETO. Despite t(8;21) AML being considered as a subty...

    Authors: Wei Zhou, Siying Li, Hong Wang, Jingfeng Zhou, Shuyi Li, Guofeng Chen, Wei Guan, Xianli Fu, Clara Nervi, Li Yu and Yonghui Li
    Citation: Experimental Hematology & Oncology 2024 13:9
  48. RNA modifications have been proven to play fundamental roles in regulating cellular biology process. Recently, maladjusted N7-methylguanosine (m7G) modification and its modifiers METTL1/WDR4 have been confirmed a...

    Authors: Pan Zhao, Lin Xia, Dan Chen, Wei Xu, Huanping Guo, Yinying Xu, Bingbing Yan, Xiao Wu, Yuxia Li, Yunfang Zhang and Xi Zhang
    Citation: Experimental Hematology & Oncology 2024 13:8

Annual Journal Metrics

  • 2022 Citation Impact
    11.4 - 2-year Impact Factor
    7.3 - 5-year Impact Factor
    1.609 - SNIP (Source Normalized Impact per Paper)
    1.908 - SJR (SCImago Journal Rank)

    2023 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    100 days submission to accept (Median)

    2023 Usage
    696,150 downloads
    375 Altmetric mentions